Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 38, 2017, Pages 10202-10207

  Cohen, Joshua D ^a,b   Javed, Ammar A ^a   Thoburn, Christopher ^a   Wong, Fay ^a   Tie, Jeanne ^c,d,e   Gibbs, Peter ^c,d,e   Schmidt, C Max ^f   Yip Schneider, Michele T ^f   Allen, Peter J ^g   Schattner, Mark ^g   Brand, Randall E ^h   Singhi, Aatur D ^h   Petersen, Gloria M ⁱ   Hong, Seung Mo ^j   Kim, Song Cheol ^j   Falconi, Massimo ^k   Doglioni, Claudio ^k   Weiss, Matthew J ^a   Ahuja, Nita ^a   He, Jin ^a   Makary, Martin A ^a   Maitra, Anirban ^l   Hanash, Samir M ^l   Dal Molin, Marco ^a   Wang, Yuxuan ^a   Li, Lu ^m   Ptak, Janine ^a   Dobbyn, Lisa ^a   Schaefer, Joy ^a   Silliman, Natalie ^a   Popoli, Maria ^a   Goggins, Michael G ^a   Hruban, Ralph H ^a   Wolfgang, Christopher L ^a   Klein, Alison P ^a,m   Tomasetti, Cristian ^a,m   Papadopoulos, Nickolas ^a   Kinzler, Kenneth W ^a   Vogelstein, Bert ^a   Lennon, Anne Marie ^a   more..

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e WESTERN HEALTH   (Australia)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ MAYO CLINIC   (United States)

^j University of Ulsan College of Medicine   (South Korea)

^k SAN RAFFAELE HOSPITAL   (Italy)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

Circulating tumor DNA; Early cancer detection; Liquid biopsy; Pancreatic cancer; Protein biomarkers

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD31 ANTIGEN; CD44V ANTIGEN; CHLOROPLAST DNA; CYTOKERATIN 19 FRAGMENT; DICKKOPF 1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR; HUMAN EPIDIDYMIS PROTEIN 4; INTERLEUKIN 6; INTERLEUKIN 8; K RAS PROTEIN; KALLIKREIN 6; LEPTIN; MESOTHELIN; MIDKINE; OSTEOPONTIN; OSTEOPROTEGERIN; PROLACTIN; PROTEIN TYROSINE KINASE; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR PROTEIN; UROKINASE RECEPTOR; CIRCULATING TUMOR DNA; KRAS PROTEIN, HUMAN; PROTEIN P21;

AGED; ALLELE; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CODON; COHORT ANALYSIS; CONTROLLED STUDY; DNA BARCODING; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; LIQUID BIOPSY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; BLOOD; CASE CONTROL STUDY; EVALUATION STUDY; FEMALE; GENETICS; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; TUMOR SUPPRESSOR GENE;

AGED; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; CIRCULATING TUMOR DNA; FEMALE; GENES, P53; HUMANS; LIQUID BIOPSY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85029555696     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1704961114     Document Type: Article

References (62)

1. Rahib L, et al. (2014) Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74: 2913–2921.
2. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30.
3. Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371: 2140–2141.
4. Ansari D, et al. (2017) Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. Br J Surg 104:600–607.
5. Jung KW, et al. (2007) Clinicopathological aspects of 542 cases of pancreatic cancer: A special emphasis on small pancreatic cancer. J Korean Med Sci 22(Suppl):S79–S85.
6. Egawa S, et al. (2004) Clinicopathological aspects of small pancreatic cancer. Pancreas 28:235–240.
7. Ishikawa O, et al. (1999) Minute carcinoma of the pancreas measuring 1 cm or less in diameter–collective review of Japanese case reports. Hepatogastroenterology 46:8–15.
8. Tsuchiya R, et al. (1986) Collective review of small carcinomas of the pancreas. Ann Surg 203:77–81.
9. Howlader N, et al. (2016) SEER Cancer Statistics Review, 1975-2013 (National Cancer Institute, Bethesda, MD) Available at https://seer.cancer.gov/csr/1975_2013/. Accessed April 25, 2017.
10. Bozic I, et al. (2013) Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2:e00747.
11. Semrad TJ, Fahrni AR, Gong IY, Khatri VP (2015) Integrating chemotherapy into the management of oligometastatic colorectal cancer: Evidence-based approach using clinical trial findings. Ann Surg Oncol 22(Suppl 3):S855–S862.
12. Moertel CG, et al. (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321–326.
13. André T, et al. (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116.
14. Dy GK, et al. (2009) Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: A North Central Cancer Treatment Group review of 3811 patients, N0144. Clin Colorectal Cancer 8:88–93.
15. Huang AC, et al. (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60–65.
16. Liotta LA, Petricoin EF, 3rd (2003) The promise of proteomics. Clin Adv Hematol Oncol 1:460–462.
17. Lennon AM, Goggins M (2010) Diagnostic and therapeutic response markers. Pancreatic Cancer (Springer, New York), pp 675–701.
18. Clarke-Pearson DL (2009) Clinical practice. Screening for ovarian cancer. N Engl J Med 361:170–177.
19. Locker GY, et al.; ASCO (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313–5327.
20. Haber DA, Velculescu VE (2014) Blood-based analyses of cancer: Circulating tumor cells and circulating tumor DNA. Cancer Discov 4:650–661.
21. Dawson SJ, et al. (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199–1209.
22. Bettegowda C, et al. (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24.
23. Kinde I, et al. (2013) Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 5:167ra4.
24. Wang Y, et al. (2015) Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med 7:293ra104.
25. Wang Y, et al. (2015) Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci USA 112: 9704–9709.
26. Wang Y, et al. (2016) Diagnostic potential of tumor DNA from ovarian cyst fluid. ElLife 5:e15175.
27. Springer S, et al. (2015) A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology 149:1501–1510.
28. Forshew T, et al. (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4:136ra68.
29. Vogelstein B, Kinzler KW (1999) Digital PCR. Proc Natl Acad Sci USA 96:9236–9241.
30. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B (2003) Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 100:8817–8822.
31. Vogelstein B, et al. (2013) Cancer genome landscapes. Science 339:1546–1558.
32. Allen PJ, et al. (2017) Multi-institutional validation study of the American Joint Commission on Cancer (8th edition) changes for T and N staging in patients with pancreatic adenocarcinoma. Ann Surg 265:185–191.
33. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B (2011) Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA 108:9530–9535.
34. Zhou W, et al. (1998) Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 7:109–112.
35. O’Brien DP, et al. (2015) Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: Implications for early disease detection. Clin Cancer Res 21:622–631.
36. Kim JE, et al. (2004) Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19: 182–186.
37. Uhlén M, et al. (2015) Proteomics. Tissue-based map of the human proteome. Science 347:1260419.
38. Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E (2000) The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology 47:1750–1752.
39. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR (1995) Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 55:1129–1138.
40. Ikematsu S, et al. (2000) Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 83:701–706.
41. Koopmann J, et al. (2004) Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13:487–491.
42. Levina VV, et al. (2009) Biological significance of prolactin in gynecologic cancers. Cancer Res 69:5226–5233.
43. Thorpe JD, et al. (2007) Effects of blood collection conditions on ovarian cancer serum markers. PLoS One 2:e1281.
44. Jones S, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806.
45. Biankin AV, et al.; Australian Pancreatic Cancer Genome Initiative (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 399–405.
46. Waddell N, et al.; Australian Pancreatic Cancer Genome Initiative (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495–501.
47. Lennon AM, et al. (2014) The early detection of pancreatic cancer: What will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res 74:3381–3389.
48. Xie M, et al. (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20:1472–1478.
49. Jaiswal S, et al. (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488–2498.
50. Genovese G, et al. (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371:2477–2487.
51. Dong T, Liu CC, Petricoin EF, Tang LL (2014) Combining markers with and without the limit of detection. Stat Med 33:1307–1320.
52. Capello M, et al. (2017) Sequential validation of blood-based protein biomarker candidates for early-stage pancreatic cancer. J Natl Cancer Inst 109:djx004.
53. Le Calvez-Kelm F, et al. (2016) KRAS mutations in blood circulating cell-free DNA: A pancreatic cancer case-control. Oncotarget 7:78827–78840.
54. Wilcox CM, et al. (2015) Chronic pancreatitis pain pattern and severity are independent of abdominal imaging findings. Clin Gastroenterol Hepatol 13:552–560, quiz e528–e559.
55. Frøkjær JB, Olesen SS, Drewes AM (2013) Fibrosis, atrophy, and ductal pathology in chronic pancreatitis are associated with pancreatic function but independent of symptoms. Pancreas 42:1182–1187.
56. Bahuva R, Walsh RM, Kapural L, Stevens T (2013) Morphologic abnormalities are poorly predictive of visceral pain in chronic pancreatitis. Pancreas 42:6–10.
57. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380.
58. Thomas DS, et al. (2015) Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer 113: 268–274.
59. Di Renzo MF, et al. (1995) Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1:147–154.
60. El-Tanani MK, et al. (2006) The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17:463–474.
61. Kalinich M, et al. (2017) An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci USA 114: 1123–1128.
62. Chari ST, et al. (2005) Probability of pancreatic cancer following diabetes: A population-based study. Gastroenterology 129:504–511.